Ibrutinib CAS 936563-96-1 Ubunyulu > 99.5% (HPLC) API

Inkcazelo emfutshane:

Igama leKhemikhali: Ibrutinib

CAS: 936563-96-1

Ubunyulu: >99.5% (HPLC)

Imbonakalo: Imhlophe ukuya kwi-Off-White Crystal Powder

Ibrutinib yi-BTK inhibitor esetyenziselwa ukuphatha i-Chronic Lymphocytic Leukemia (CLL) kunye neMantle Cell Lymphoma (MCL)

Qhagamshelana: UGqr. Alvin Huang

Iselula/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iimveliso ezinxulumeneyo

Iithegi zeMveliso

Inkcazo:

I-Ibrutinib eNxulumene nayo:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
I-4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Iipropati zeMichiza:

Igama leMchiza	Ibrutinib
Izithethantonye	1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- Nye;PCI-32765
Inombolo yeCAS	936563-96-1
Ubume beStokhwe	Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni
Ifomula yeemolekyuli	I-C25H24N6O2
Ubunzima beMolekyuli	440.50
Uphawu	Ruifu Chemical

Iinkcukacha:

Into	Iinkcukacha
Imbonakalo	Mhlophe ukuya kuMhlophe wePowder yeCrystal
Ukuchongwa	I-IR;HPLC
Ilahleko ekomisweni	<0.50%
Intsalela kwi-Ignition	≤0.10%
Iintsimbi ezinzima (njenge Pb)	≤20ppm
Nakuphi na Ukungacoceki Okukodwa	≤0.20%
Ukungcola ngokupheleleyo	<0.50%
Ubunyulu / Indlela yokuHlalutya	>99.5% (HPLC)
Umgangatho woVavanyo	Umgangatho woShishino
Ukusetyenziswa	API

Ukupakishwa kunye noGcino:

Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi.

Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma.

Izinto eziluncedo:

FAQ:

Isicelo:

Ibrutinib (i-CAS: 936563-96-1) i-inhibitor ye-Bruton tyrosine kinase (BTK) yonyango lwe-lymphocytic leukemia engapheliyo (CLL) kunye ne-mantle cell lymphoma (MCL).Zombini i-MCL kunye ne-CLL zeze-B-cell non-Hodgkin's lymphoma, ephikisayo kwaye ithanda ukuphinda ibuyele.I-chemoimmunotherapy esetyenziswa ngokuqhelekileyo ayijoliswanga, kwaye i-grade 3 okanye i-4 reactions ezimbi zihlala zenzeka.I-Ibrutinib inokudibanisa ne-BTK, eyimfuneko ekubunjweni, ukwahlula, ukunxibelelana kunye nokusinda kwe-lymphocytes ye-B, kwaye ngokungenakunqandwa ukuvimbela umsebenzi we-BTK, ukuthintela ngokufanelekileyo ukwanda kunye nokusinda kweeseli ze-tumor.Ukongezelela, ixutywa ngokukhawuleza emva kokulawulwa komlomo, ubuninzi be-plasma yoxinaniso lufikelele kwi-1 ~ 2h, kwaye ukusabela okungalunganga kwibakala 1 okanye i-2, eya kuba yinto entsha yonyango lwe-CLL kunye ne-MCL.NgoNovemba 13, i-2013, i-US FDA ukukhawuleza inkampani evunyiweyo kaJohnson & Johnson kunye ne-United States Imbruvica (igama eliqhelekileyo: Ibrutinib) kunyango lwe-mantle cell lymphoma (MCL).Ibrutinib, inikwe i-breakthrough Therapy status yi-FDA ngoFebruwari 2013 kwaye yamkelwa i-MCL ngoNovemba 13, 2013 kunye ne-CLL ngoFebruwari 12, 2014, ngokulandelanayo.